Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare adds fourth drug compendium for Part B coverage

Executive Summary

Elsevier Gold Standard's Clinical Pharmacology is officially recognized as a valid reference for determining off-label coverage of cancer drugs under Medicare Part B. The decision completes CMS' review of compendia recognition requests received earlier this year. Of four compendia nominated, three have been officially recognized by the agency; the other two are Thomson Micromedex's DrugDex and the National Comprehensive Cancer Network Drugs & Biologics Compendium. They join the currently recognized compendium that is still in print - American Hospital Formulary Service-Drug Information - bringing to four the number of officially recognized compendia that now may be used for coverage decisions
Advertisement
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS049841

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel